U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Aggressive T-Cell Non-Hodgkin Lymphoma

MedGen UID:
1791570
•Concept ID:
C5555129
•
Neoplastic Process

Definition

An aggressive T-cell non-Hodgkin lymphoma that is resistant to treatment. [from NCI]

Professional guidelines

PubMed

Critical care management of chimeric antigen receptor T-cell therapy recipients.
Shimabukuro-Vornhagen A, Böll B, Schellongowski P, Valade S, Metaxa V, Azoulay E, von Bergwelt-Baildon M
CA Cancer J Clin 2022 Jan;72(1):78-93. Epub 2021 Oct 6 doi: 10.3322/caac.21702. PMID: 34613616
Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics.
Ahmed Z, Afridi SS, Shahid Z, Zamani Z, Rehman S, Aiman W, Khan M, Mir MA, Awan FT, Anwer F, Iftikhar R
Clin Lymphoma Myeloma Leuk 2021 Nov;21(11):e865-e875. Epub 2021 Jun 24 doi: 10.1016/j.clml.2021.06.012. PMID: 34330673
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A, Soma L
Cancer Treat Res 2019;176:127-144. doi: 10.1007/978-3-319-99716-2_6. PMID: 30596216

Recent clinical studies

Etiology

CAR T-cell therapy for B-cell lymphoma.
Denlinger N, Bond D, Jaglowski S
Curr Probl Cancer 2022 Feb;46(1):100826. Epub 2021 Dec 25 doi: 10.1016/j.currproblcancer.2021.100826. PMID: 35012754Free PMC Article
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR
N Engl J Med 2022 Feb 17;386(7):629-639. Epub 2021 Dec 14 doi: 10.1056/NEJMoa2116596. PMID: 34904798
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT
Lancet Oncol 2021 Oct;22(10):1403-1415. Epub 2021 Sep 10 doi: 10.1016/S1470-2045(21)00375-2. PMID: 34516954
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M
Cochrane Database Syst Rev 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2. PMID: 34515338Free PMC Article
Enteropathy-Associated T cell Lymphoma.
Al Somali Z, Hamadani M, Kharfan-Dabaja M, Sureda A, El Fakih R, Aljurf M
Curr Hematol Malig Rep 2021 Apr;16(2):140-147. Epub 2021 May 19 doi: 10.1007/s11899-021-00634-4. PMID: 34009525

Diagnosis

How we treat NK/T-cell lymphomas.
Tse E, Zhao WL, Xiong J, Kwong YL
J Hematol Oncol 2022 Jun 3;15(1):74. doi: 10.1186/s13045-022-01293-5. PMID: 35659326Free PMC Article
Follicular Lymphoma: a Focus on Current and Emerging Therapies.
Cahill KE, Smith SM
Oncology (Williston Park) 2022 Feb 8;36(2):97-106. doi: 10.46883/2022.25920946. PMID: 35180337Free PMC Article
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT
Lancet Oncol 2021 Oct;22(10):1403-1415. Epub 2021 Sep 10 doi: 10.1016/S1470-2045(21)00375-2. PMID: 34516954
Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics.
Ahmed Z, Afridi SS, Shahid Z, Zamani Z, Rehman S, Aiman W, Khan M, Mir MA, Awan FT, Anwer F, Iftikhar R
Clin Lymphoma Myeloma Leuk 2021 Nov;21(11):e865-e875. Epub 2021 Jun 24 doi: 10.1016/j.clml.2021.06.012. PMID: 34330673
Enteropathy-Associated T cell Lymphoma.
Al Somali Z, Hamadani M, Kharfan-Dabaja M, Sureda A, El Fakih R, Aljurf M
Curr Hematol Malig Rep 2021 Apr;16(2):140-147. Epub 2021 May 19 doi: 10.1007/s11899-021-00634-4. PMID: 34009525

Therapy

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL.
Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, Zhang L, Wei G, Tian Y, Zhao K, Chen A, Tan B, Cui J, Li D, Li Y, Qi Y, Wang D, Wu Y, Li D, Du B, Liu M, Huang H
Nature 2022 Sep;609(7926):369-374. Epub 2022 Aug 31 doi: 10.1038/s41586-022-05140-y. PMID: 36045296Free PMC Article
How we treat NK/T-cell lymphomas.
Tse E, Zhao WL, Xiong J, Kwong YL
J Hematol Oncol 2022 Jun 3;15(1):74. doi: 10.1186/s13045-022-01293-5. PMID: 35659326Free PMC Article
CAR T-cell therapy for B-cell lymphoma.
Denlinger N, Bond D, Jaglowski S
Curr Probl Cancer 2022 Feb;46(1):100826. Epub 2021 Dec 25 doi: 10.1016/j.currproblcancer.2021.100826. PMID: 35012754Free PMC Article
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ
J Clin Oncol 2021 Jun 20;39(18):1959-1970. Epub 2021 Mar 19 doi: 10.1200/JCO.20.03175. PMID: 33739857Free PMC Article
Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.
Abramson JS
Transfus Med Rev 2020 Jan;34(1):29-33. Epub 2019 Aug 29 doi: 10.1016/j.tmrv.2019.08.003. PMID: 31677848

Prognosis

How we treat NK/T-cell lymphomas.
Tse E, Zhao WL, Xiong J, Kwong YL
J Hematol Oncol 2022 Jun 3;15(1):74. doi: 10.1186/s13045-022-01293-5. PMID: 35659326Free PMC Article
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR
N Engl J Med 2022 Feb 17;386(7):629-639. Epub 2021 Dec 14 doi: 10.1056/NEJMoa2116596. PMID: 34904798
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M
Cochrane Database Syst Rev 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2. PMID: 34515338Free PMC Article
Enteropathy-Associated T cell Lymphoma.
Al Somali Z, Hamadani M, Kharfan-Dabaja M, Sureda A, El Fakih R, Aljurf M
Curr Hematol Malig Rep 2021 Apr;16(2):140-147. Epub 2021 May 19 doi: 10.1007/s11899-021-00634-4. PMID: 34009525
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ
J Clin Oncol 2021 Jun 20;39(18):1959-1970. Epub 2021 Mar 19 doi: 10.1200/JCO.20.03175. PMID: 33739857Free PMC Article

Clinical prediction guides

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL.
Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, Zhang L, Wei G, Tian Y, Zhao K, Chen A, Tan B, Cui J, Li D, Li Y, Qi Y, Wang D, Wu Y, Li D, Du B, Liu M, Huang H
Nature 2022 Sep;609(7926):369-374. Epub 2022 Aug 31 doi: 10.1038/s41586-022-05140-y. PMID: 36045296Free PMC Article
How we treat NK/T-cell lymphomas.
Tse E, Zhao WL, Xiong J, Kwong YL
J Hematol Oncol 2022 Jun 3;15(1):74. doi: 10.1186/s13045-022-01293-5. PMID: 35659326Free PMC Article
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR
N Engl J Med 2022 Feb 17;386(7):629-639. Epub 2021 Dec 14 doi: 10.1056/NEJMoa2116596. PMID: 34904798
Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, Andreadis C
Am J Hematol 2021 Oct 1;96(10):1295-1312. Epub 2021 Aug 13 doi: 10.1002/ajh.26301. PMID: 34310745Free PMC Article
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ
J Clin Oncol 2021 Jun 20;39(18):1959-1970. Epub 2021 Mar 19 doi: 10.1200/JCO.20.03175. PMID: 33739857Free PMC Article

Recent systematic reviews

Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
Wang Z, Zhou H, Xu J, Wang J, Niu T
Front Immunol 2022;13:1070660. Epub 2023 Jan 4 doi: 10.3389/fimmu.2022.1070660. PMID: 36685572Free PMC Article
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M
Cochrane Database Syst Rev 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2. PMID: 34515338Free PMC Article
Allogeneic Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T-cell Lymphoma.
Peng YY, Xiong YY, Zhang LX, Wang J, Zhang HB, Xiao Q, Guo SL
Turk J Haematol 2021 Jun 1;38(2):126-137. Epub 2021 Feb 4 doi: 10.4274/tjh.galenos.2021.2020.0438. PMID: 33535731Free PMC Article
Advances and Perspectives in the Treatment of T-PLL.
Braun T, von Jan J, Wahnschaffe L, Herling M
Curr Hematol Malig Rep 2020 Apr;15(2):113-124. doi: 10.1007/s11899-020-00566-5. PMID: 32034661Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...